Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4067-4075

  Cheng, Ann Lii ^a   Kang, Yoon Koo ^c   Lin, Deng Yn ^b   Park, Joong Won ^e   Kudo, Masatoshi ^f   Qin, Shukui ^h   Chung, Hyun Cheol ^d   Song, Xiangqun ⁱ   Xu, Jianming ^j   Poggi, Guido ^k   Omata, Masao ^g   Lowenthal, Susan Pitman ^m   Lanzalone, Silvana ^l   Yang, Liqiang ^l   Lechuga, Maria Jose ^l   Raymond, Eric ⁿ  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

^f KINDAI UNIVERSITY HOSPITAL   (Japan)

^g Yamanashi Prefectural Central Hospital   (Japan)

^h Nanjing Bayi Hospital   (China)

ⁱ China Mobile Group the Guangxi Zhuang Autonomous Region Co Ltd   (China)

^j Beijing 307 Hospital   (China)

^k IRCCS   (Italy)

^l PFIZER INC   (United States)

^m Pfizer Ltd   (United States)

ⁿ BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASCITES; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATALITY; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INTERACTIVE VOICE RESPONSE SYSTEM; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ADOLESCENT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PYRROLES; YOUNG ADULT;

EID: 84891915708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8372     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011
3. Perz JF, Armstrong GL, Farrington LA, et al: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538, 2006
4. Smedile A, Bugianesi E: Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 9:291-293, 2005
5. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study. J Clin Oncol 20:1775-1785, 2002
6. Yao DF, Wu XH, Zhu Y, et al: Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4:220-226, 2005
7. Zhang ZL, Liu ZS, Sun Q: Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 12:4241-4245, 2006
8. Mäkinen T, Veikkola T, Mustjoki S, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGFC/D receptor VEGFR-3. EMBO J 20:4762-4773, 2001
9. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
10. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1Rdependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
11. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605, 2003
12. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
13. Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006
14. Kodera Y, Katanasaka Y, Kitamura Y, et al: Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13:R66, 2011
15. Faivre S, Demetri G, Sargent W, et al: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745, 2007
16. Faivre S, Raymond E, Boucher E, et al: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol 10:794-800, 2009
17. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27:3027-3035, 2009
18. Koeberle D, Montemurro M, Samaras P, et al: Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Res (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 15:285-292, 2010
19. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329-338, 1999
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:359-378, 2008
22. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
23. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
24. Freidlin B, Korn EL, George SL, et al: Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 25:5019-5023, 2007
25. Cancer of the Liver Italian Program Investigators: Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma-The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31: 840-845, 2000
26. Cheng A, Kang Y, Lin D, et al: Phase 3 trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: 256s, 2011 (suppl; abstr 4000)
27. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
28. Hoffman K, Glimm H, Radeleff B, et al: Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation: HeiLivCa [ISRCTN24081794]. BMC Cancer 8:349, 2008
29. Bruix J, Raoul JL, Sherman M, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57:821-829, 2012
30. Ito Y, Sasaki Y, Horimoto M, et al: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951-958, 1998
31. Schmidt CM, McKillop IH, Cahill PA, et al: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236:54-58, 1997
32. Aoki H, Hayashi J, Moriyama M, et al: Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol 74:1736-1741, 2000
33. Giambartolomei S, Covone F, Levrero M, et al: Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20:2606-2610, 2001
34. Bürckstümmer T, Kriegs M, Lupberger J, et al: Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett 580:575-580, 2006
35. Schmitz KJ, Wohlschlaeger J, Lang H, et al: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48:83-90, 2008
36. Himmelsbach K, Sauter D, Baumert TF, et al: New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replication. Gut 58:1644-1653, 2009
37. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 64:7099-7109, 2004
38. Chen KF, Tai WT, Huang JW, et al: Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem 46: 2845-2851, 2011
39. Tai WT, Cheng AL, Shiau CW, et al: Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 55:1041-1048, 2011
40. Ou DL, Shen YC, Yu SL, et al: Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 70:9309-9318, 2010
41. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008
42. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60, 2010
43. Je Y, Schutz FA, Choueiri TK: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974, 2009
44. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
45. Escudier B, Roigas J, Gillessen S, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokinerefractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075, 2009
46. George S, Blay JY, Casali PG, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968, 2009